Partnering in Respiratory Diseases
Boehringer Ingelheim is a leader in respiratory medicine with a 100-year history of innovation in this area. Our growing portfolio of partnerships in respiratory diseases includes collaborations with world-leading academic institutions as well as biotech partnerships and innovative scientific crowdsourcing projects. We are actively pursuing new early-science collaborations in our areas of partnering interest and look forward to expanding our community of innovation partners.
Our experience
We have launched several treatments in a range of respiratory conditions in areas of high unmet patient need including asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
Our scientists are working together with their academic and industry partners to offer patients and doctors improved therapies with high efficacy, few side effects and convenient dosage forms and regimens.
Our research focus
Our current research efforts in respiratory diseases focus on areas of significant unmet need including: IPF, progressive fibrosing interstitial lung disease and cystic fibrosis.
Our partnering interests
We are further strengthening our existing portfolio for the treatment of respiratory diseases through in-licensing and external collaborations at research, pre-clinical and clinical stages.
Specifically, our areas of partnering interest include:
- IPF/PF-ILD: Block of pro-fibrotic signaling beyond standard of care
- Disease-modifying therapies for respiratory indications
- Approaches to induce lung regeneration and repair mechanisms
We are also interested in the following research areas:
- Aberrant epithelial sensing
- Epithelial-fibroblast interactions
- Dysregulated macrophage function respiratory diseases
Related Content
